32 results about "Cardiomyocyte proliferation" patented technology

The invention relates to compostions and methods for promoting cellular proliferation and de-differentiation of cells into stem cells to foster tissue regeneration. Specifically, the invention relates to transiently administering a microRNA (miR) or its mimic for promoting cardiomyocyte proliferation and cardiac regeneration.

An Agrin peptide which induces proliferation of cardiomyocytes for treating a heart disease is provided.

The invention is a method for treating a heart disease, in particular acute myocardial infarction (AMI) in a subject comprising the step of administering to the subject a Tjp1 inhibitor, wherein administration of said Tjp1 inhibitor promotes cardiomyocyte proliferation. The invention further includes use of Tjp1 inhibitor in the manufacture of a medicament for a heart disease, a patch, and a nucleic acid encoding a Tjp1 inhibitor. In a particular embodiment, the Tjp1 inhibitor is a nucleic acid, i.e. an siRNA or shRNA of Tjp1. The invention also includes administration of said Tjp1 inhibitor in combination with Neuregulin-1 (NRG1 ), Fibroblast growth factor (FGF), Vascular endothelial growth factor (VEGF) or Follistatin-like 1 (Fst1 ) and wherein said inhibitor is delivered in an adeno-associated virus of serotype 9 (AAV 9).

The invention discloses a medicine application of BML-284. The use is the application of BML-284 or a pharmaceutically acceptable salt thereof in the preparation of drugs for promoting cardiomyocyte proliferation. The present invention proves through experiments that BML-284 can promote the proliferation of rat cardiomyocytes. Therefore, BML‑284 can be used in related fields such as the preparation of drugs for promoting myocardial cell proliferation and drugs for treating or preventing heart disease, providing a new drug and treatment idea for treating or preventing heart disease such as myocardial infarction.

The invention discloses application of lysophosphatidic acid, a lysophosphatidic acid receptor 3 and a lysophosphatidic acid receptor 3 agonist and relates to the field of biomedicine. The study findsout that lysophosphatidic acid or the lysophosphatidic acid receptor 3 or the lysophosphatidic acid receptor 3 agonist can promote cardiomyocyte proliferation and inhibit cardiomyocyte apoptosis to repair damaged myocardia, significantly reduce myocardial infarct areas and significantly improve cardiac functions after myocardial infarction, and the effect is obvious. Therefore, lysophosphatidic acid, the lysophosphatidic acid receptor 3 and the lysophosphatidic acid receptor 3 agonist can be used in the field of preparation of medicine, preparations and the like for treating or preventing heart diseases, and new medicine and a new treatment idea are provided for treating or preventing heart diseases such as ischemic heart disease.

An expression vector capable of disrupting the silencing of cell cycle genes in adult cells, such as adult cardiac myocytes and other quiescent cells in terminally differentiated tissues, comprising: (a) a nucleic acid sequence encoding lysine-specific demethylase 4D (KDM4D); (b) a promoter that induces or effects overexpression of KDM4D, wherein the promoter is operably linked to the nucleic acid sequence; and (c) a regulatory element that inducibly represses the overexpression of KDM4D. The vector can be administered to a subject in a method for inducing tissue-specific hyperplasia in a mammal, including cardiomyocyte proliferation. The method provides for regenerative therapy, including improving cardiac function after myocardial infarct and other forms of cardiac damage.

The invention discloses a medicine application of phenylephrine. The use is the application of phenylephrine or its pharmaceutically acceptable salts and esters in the preparation of drugs for promoting cardiomyocyte proliferation. The present invention proves through experiments that phenylephrine can promote the proliferation of rat cardiomyocytes. Therefore, phenylephrine can be used in related fields such as preparation of drugs for promoting myocardial cell proliferation and drugs for treating or preventing heart disease, providing a new drug and treatment idea for treating or preventing heart disease such as myocardial infarction.

The present invention provides the application of miRNA708 and / or microRNA of cluster 301 in improving heart function. Specifically, microRNAs of miRNA708 and / or 301 clusters can (i) promote cardiomyocyte proliferation; (ii) improve cardiomyocyte anti-hypoxic stress ability; (iii) reduce cardiomyocyte apoptosis and death; (iv) induce myocardial cell proliferation; Proliferation and differentiation of stem cells; and / or (v) protecting cardiomyocytes from hypoxic stimulation.

The present disclosure provides microRNA-based therapies using a hydrogel delivery system that provides regenerative approach to myocardial infarction by targeting cardiomyocytes. The hydrogel provides for local and sustained cardiac delivery of microRNAs, such miR-302 mimics that can be used to promote cardiomyocyte proliferation. Also provided are compositions suitable for local and sustained release and methods for intramyocardial gel delivery of a miRNA oligonucleotide.

The present invention addresses the problems of providing a method for proliferating cardiomyocytes using a miRNA that promotes the proliferation of cardiomyocytes, a vector for use in the treatment of heart disease, a pharmaceutical composition for treating heart disease, and so forth.The present invention provides a method for proliferating cardiomyocytes using a miRNA having the cardiomyocyte proliferation promoting action, a vector for use in the treatment of heart disease that comprises said miRNA, a pharmaceutical composition for treating heart disease that comprises said vector, and so forth. A particularly preferred miRNA is one that is selected from the group consisting of mature miRNAs, i.e., miR-148a, miR-148b, miR-152, and miR-373, and precursors of said miRNAs, as well as variants and analogs thereof.

The present invention addresses the problems of providing a method for proliferating cardiomyocytes using a miRNA that promotes the proliferation of cardiomyocytes, a vector for use in the treatment of heart disease, a pharmaceutical composition for treating heart disease, and so forth.The present invention provides a method for proliferating cardiomyocytes using a miRNA having the cardiomyocyte proliferation promoting action, a vector for use in the treatment of heart disease that comprises said miRNA, a pharmaceutical composition for treating heart disease that comprises said vector, and so forth. A particularly preferred miRNA is one that is selected from the group consisting of mature miRNAs, i.e., miR-148a, miR-148b, miR-152, and miR-373, and precursors of said miRNAs, as well as variants and analogs thereof.

The invention discloses a new medicine application of AZD3965. The new use is the application of AZD3965 or its pharmaceutically acceptable salts and esters in the preparation of drugs for promoting cardiomyocyte proliferation. The present invention proves through experiments that AZD3965 can promote the proliferation of cardiomyocytes in rats and the cytokinesis of cardiomyocytes in newborn mice with MADM. Therefore, AZD3965 can be used in related fields such as preparation of drugs for promoting myocardial cell proliferation and drugs for treating or preventing heart disease, providing a new drug and treatment idea for treating or preventing heart disease such as myocardial infarction.

A combination of active agents selected from a FoxM1 enhancer, an Id1 enhancer, and a JNK3 inhibitor and the uses thereof in promoting cardiomyocyte proliferation and treating heart diseases in a subject in need of the treatment.